ALIBABA-CLOUD
19.3.2020 05:26:06 CET | Business Wire | Press release
Alibaba Cloud, the data intelligence backbone of Alibaba Group, said today it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.
The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.
The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud’s solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.
While DingTalk might be better-known for supporting more than 120 million students across China with their live-streamed online classes, the team has taken it up a notch to launch DingTalk’s International Medical Expert Communication Platform , hosted on Alibaba Cloud. It provides a means of free communication for medical workers all over the world to directly contact doctors from medical institutions such as the First Affiliated Hospital of Zhejiang University and others in China, who have been on the frontline of the COVID-19 battle.
Through video conferencing and real-time AI translation into 11 languages (Arabic, Bahasa, Chinese, English, French, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), Alibaba Cloud aims to build a virtual community, inviting Chinese doctors to share their experiences and answer questions from global peers.
From Alibaba DAMO Academy, a global research initiative by Alibaba, three proven solutions are being made available via free trial for medical professionals and research institutes worldwide. Alibaba Cloud will work with local partners to deploy relevant services and solutions in accordance with local laws and regulations.
Epidemic Prediction Solution models epidemic characteristics of COVID-19 in a particular region, providing estimates of size, peak time and duration of the epidemic, as well as the spreading trends under three conditions - optimistic, neutral, and pessimistic. Based on machine learning, the algorithm was already tested on 31 provincial data in China and averaged 98% accuracy. It can serve as a reference to policymakers and medical researchers on prevention and control measures, medical resource allocation and travel advisories.
CT Image Analytics Solution is a CT image analytics technology service that can significantly improve testing accuracy and detection efficiency for diagnosing COVID-19. With deep-learning algorithms trained by data in China, the trained model can predict the probability of different pneumonia types, including the variety associated with COVID-19. It also performs computations of the proportion of lesions and the affected volume ratio to the entire lungs, by using the lung segmentation method. The whole test takes about 3 to 4 seconds to run and 15 to 16 seconds of transmission time, making it nearly 60 times faster than human detection. More than 160 hospitals in China are currently using the solution.
Genome Sequencing for Coronavirus Diagnostic Solution , an AI algorithm from Alibaba DAMO Academy and running on Alibaba Cloud, is a virus genome sequencing solution for coronavirus analytics, including viral genetic data screening, evolutionary analysis, protein structure analysis, and diagnostic reporting. It can complete the diagnosis of new coronavirus within 14 hours, which is five times faster than other available sequencing solutions in China. It can screen more than 20 people simultaneously, making the averaged time for each sample just around half an hour, much shorter than the normal two hours with the PCR method. The solution helps disease control centers, hospitals and clinics, and laboratories to address challenges such as insufficient nucleic acid detection capacity, high false-negative rates of the PCR method, and possible virus mutations.
Supporting advanced innovations during emergencies like COVID-19 requires extremely scalable supercomputing power. For this, Alibaba Cloud offers Elastic High-Performance Computing (E-HPC) Solution for Life Sciences , a cloud-native high-performance computing cluster solution designed for researchers working on life sciences applications, especially for Computational-Driven-Drug-Design (CDDD) and AI-Driven-Drug-Design (AIDDD). The solution already supports 20 research groups in China. For example, the intelligent CT diagnostic system on COVID-19 pneumonia developed by Tsinghua University can complete diagnosing in 10 seconds, and the performance of gene assembly by Sun Yat-sen University is accelerated by 25% utilizing the solution. Alibaba Cloud has also partnered with Global Health Drug Discovery Institute (GHDDI) in Beijing to launch an AI-driven-drug-discovery platform based on E-HPC.
For those looking to learn more about key lessons and experience from doctors and other medical personnel at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), the Jack Ma Foundation and Alibaba Foundation have also shared a handbook from the medical personnel covering what they’ve learned every step of the way, from screening to diagnosis and treatment of patients who contracted COVID-19. Medical personnel can download the handbook at https://covid-19.alibabacloud.com/ .
For more information about the above solutions available for global medical communities and businesses, please visit: https://www.alibabacloud.com/campaign/supports-your-business-anytime
Notes to the editors
The information in this press release should not be interpreted as offering medical advice or diagnostics, which should be given exclusively by authorized medical professionals in relevant jurisdiction. All data referred to are those as of writing of this summary, and Alibaba Cloud explicitly disclaim any warranty for accuracy or performance.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the data intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom